Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures.
about
Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenograftsBioengineering Models for Breast Cancer ResearchSteroid hormones, steroid receptors, and breast cancer stem cellsOne mouse, one patient paradigm: New avatars of personalized cancer therapyPatient-derived xenograft models of breast cancer and their predictive powerCurrent status and evolution of preclinical drug development models of epithelial ovarian cancerProgesterone receptor modulates ERα action in breast cancer.Patient-derived tumour xenografts for breast cancer drug discoveryFrom bench to bedside: What do we know about hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer?Deciphering the divergent roles of progestogens in breast cancer.Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancerThe future of patient-derived tumor xenografts in cancer treatment.Cellular heterogeneity profiling by hyaluronan probes reveals an invasive but slow-growing breast tumor subset.Efficacy and Molecular Mechanisms of Differentiated Response to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Models of p53-Mutated Triple-Negative Breast CancerPatient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition.Progesterone downregulation of miR-141 contributes to expansion of stem-like breast cancer cells through maintenance of progesterone receptor and Stat5a.NSG Mice Provide a Better Spontaneous Model of Breast Cancer Metastasis than Athymic (Nude) Mice.The Six1 oncoprotein downregulates p53 via concomitant regulation of RPL26 and microRNA-27a-3p.184AA3: a xenograft model of ER+ breast adenocarcinoma.Progesterone-inducible cytokeratin 5-positive cells in luminal breast cancer exhibit progenitor properties.RASSF1A Promoter Methylation Levels Positively Correlate with Estrogen Receptor Expression in Breast Cancer Patients.Patient-derived breast tumor xenografts facilitating personalized cancer therapy.A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft modelsGenomic characterization of patient-derived xenograft models established from fine needle aspirate biopsies of a primary pancreatic ductal adenocarcinoma and from patient-matched metastatic sitesWhole transcriptome profiling of patient-derived xenograft models as a tool to identify both tumor and stromal specific biomarkersMolecular characterization of patient-derived human pancreatic tumor xenograft models for preclinical and translational development of cancer therapeuticsPilot studies for personalized cancer medicine: focusing on the patient for treatment selection.Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer.Labeling of Breast Cancer Patient-derived Xenografts with Traceable Reporters for Tumor Growth and Metastasis Studies.Lessons learned from the intrinsic subtypes of breast cancer in the quest for precision therapy.Prognostic and functional importance of the engraftment-associated genes in the patient-derived xenograft models of triple-negative breast cancers.Prognostic Impact of Progesterone Receptor Status in Chinese Estrogen Receptor Positive Invasive Breast Cancer Patients.Current Update of Patient-Derived Xenograft Model for Translational Breast Cancer Research.Steroid Hormone Receptor Positive Breast Cancer Patient-Derived Xenografts.Cooperative Dynamics of AR and ER Activity in Breast Cancer.The therapeutic potential of mTOR inhibitors in breast cancer.Family Matters: Collaboration and Conflict Among the Steroid Receptors Raises a Need for Group Therapy.Patient-derived xenograft (PDX) models in basic and translational breast cancer research.Fibroblast Subtypes Regulate Responsiveness of Luminal Breast Cancer to Estrogen.Characterization of patient-derived tumor xenografts (PDXs) as models for estrogen receptor positive (ER+HER2- and ER+HER2+) breast cancers.
P2860
Q24621116-CC599913-D6F9-4C18-9D43-1ED69C1F3BB1Q26770495-8212736B-CDDE-4B9F-9AEC-8AD3FD444D98Q26799113-81F97FB0-F847-43F6-8F24-4EB2F16343BDQ27023342-9F9331BB-A068-4B59-BC57-577862F95C80Q27026531-440AC0EE-48A4-4121-8EA5-5A68E72C214FQ27028117-BCC956B0-64C2-4550-B4D0-C8294F057559Q27316268-9AF4C74C-B155-4930-8A5D-06022693FA8DQ28080046-08D10532-D581-494F-A9DB-191142A939B2Q28084982-36618B24-638D-468F-B74F-59D747C41C04Q30240711-AEDEB055-5A82-444F-962C-BB49458B75BEQ30409503-FA14C7AE-52EA-40AD-B80D-52D359B27A09Q33361578-F5160170-9C3A-4100-ADF8-1F4298246E7DQ33674704-8AEF85F7-9BDB-43B2-9E32-D661773BE842Q33680293-FA197BD4-0FC5-4041-B165-915C8C12B343Q33739184-13B680CE-C646-48D9-BA71-AE1018C04F88Q35205643-8D0C96B5-FF0B-49FF-92CC-EFB485FB7204Q36143238-098A5588-70B1-43BA-8380-A21D5B39D502Q36437988-D044412C-1B63-4FA8-B0CC-7F6F77EB6F23Q36446649-DDD2637D-6DFD-4D12-94A4-7F15D7C32A6DQ36547484-A759E741-0F47-47CA-976A-50F64FAA8DC9Q36865048-1AC4A67E-8A38-47C7-8B22-3732C8D95AB6Q36903447-10B99ACC-E10D-4D76-AF5E-0DC95061E88CQ37067545-8341EB15-1EF5-4403-86AF-D60B2E10DD67Q37086209-53F1DB9A-3F47-4E6E-B6FC-58177FBACA68Q37190437-2605FC39-9BE9-40E6-AC18-49B7E0F59747Q37285542-12F5E5FA-686A-47F1-9996-ED5B2A2E8711Q37301452-09E51008-3BB9-40AF-AE90-19BD2EB50EEBQ37533025-55E30869-8F58-4AE0-A7B2-89B331AC07EDQ37580013-A95B3913-6D7E-4D0F-8808-256D5D59489DQ38213543-C61EE94F-5B9B-49D6-95A9-9530EA4E55C9Q38421751-2093434E-55D4-4060-95E6-6EA3E78B96F7Q38687389-3E3AC42D-F155-4494-AF0E-30774FB10ED3Q38689944-D72EBC90-3A13-46D3-8BA3-207D9E60555FQ38735015-FCB48DC2-BC24-4363-88A8-F1B98D0990D0Q38749913-5281B630-3814-4A55-9FCD-ACEECBF450F3Q38802412-6938D2BF-EEAC-4D2A-9921-6B347854A57AQ39005392-E19CD45A-1980-46AB-BBA4-B0CE7E76D015Q39057246-C03CB05F-5A64-4760-A87F-AB5CFB02700AQ39323439-17936585-D66A-40EE-A6AD-AC98A2BC3D57Q39787293-4028BC04-F4C9-45D2-8886-FC871A51E0B9
P2860
Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 24 July 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Patient-derived luminal breast ...... gen-dependent gene signatures.
@en
Patient-derived luminal breast ...... gen-dependent gene signatures.
@nl
type
label
Patient-derived luminal breast ...... gen-dependent gene signatures.
@en
Patient-derived luminal breast ...... gen-dependent gene signatures.
@nl
prefLabel
Patient-derived luminal breast ...... gen-dependent gene signatures.
@en
Patient-derived luminal breast ...... gen-dependent gene signatures.
@nl
P2093
P2860
P1476
Patient-derived luminal breast ...... gen-dependent gene signatures.
@en
P2093
Anthony Elias
Carol A Sartorius
Christina Finlayson
Christopher A Manuel
Chunling Li
Enos Kline
J Chuck Harrell
Jessica Finlay-Schultz
Joshua Wisell
Peter Kabos
P2860
P2888
P304
P356
10.1007/S10549-012-2164-8
P407
P577
2012-07-24T00:00:00Z